Arysta LifeScience announces the acquisition of majority shares in Devidayal Sales Limited (“DSL”).

“Arysta LifeScience continues to grow its business by focusing its investment and strategic initiatives in high-growth, emerging markets,” said Wayne Hewett, President and CEO, Arysta LifeScience corporation.  “By combining our portfolio of global products and technologies with DSL's manufacturing and distribution network for the Indian market, we are well positioned to serve customers in India as well as other international markets.”

DSL is a formulator and marketer of agrochemicals and micronutrients for the Indian and international markets.  Operating from primary offices in Mumbai and Vadodara, India, the company has a distribution network of over 7,000 channel partners across the country.  DSL operates a formulation and packing facility in Kalol, Gujarat, India that maintains specialized, small-pack capability to serve small holding growers in India and other emerging markets.

“The acquisition of DSL provides Arysta LifeScience with a platform for rapid entry into India, the third largest crop protection market in Asia,” said Soo Keong Tan, Arysta LifeScience Business Unit Head, South Asia & China. “Arysta LifeScience expects to capitalize on DSL’s professional skill to accelerate the registration and introduction of our proprietary products and technology to the Indian market.  In addition, we see significant opportunity to leverage DSL formulation and pack capabilities to better serve our customers outside India.”

“The promoters, leadership and staff of the company are very excited to join the Arysta LifeScience group and continue our work to expand our business across India,” said Tushar Devidayal, Managing Director of Devidayal Sales Limited.  “Arysta LifeScience is a supportive partner to the company’s current strategy, and we are pleased for its endorsement of our years of investment in Arysta LifeScience Acquires Majority Interest in Devidayal our customers, portfolio and employees.  We look forward to many years of future growth as a member of the Arysta LifeScience Group.”